
Recent advances in cancer research have led to the development of very expensive new drugs for cancer zzso the targeted zzso However, the introduction of these new therapeutic agents which costs are increasing could threaten the diffusion of these zzso It is thus necessary to determine whether the use of targeted therapies yields clinical benefits that justify their increasing zzso The development of companion diagnosis tests to target drugs and thus to select those patients most likely to benefit from the treatment may provide a useful means of containing the progress of health care expenditures and improve the zzso zzso In this paper, we present current estimates of health care expenditures linked to the use of targeted therapies for cancer zzso We also discuss some of the issues related to the regulatory decisions zzso and zzso concerning the zzso zzso 

